


How bioinformatics is changing cancer care

Just as no two patients are alike, no two cancers are alike. Despite advances in cancer treatment, some patients still face a lack of options, especially when it comes to rare, aggressive, or late-stage disease. **Bioinformatics** is changing this, putting highly personalized cancer treatment options in the hands of clinicians. Here's how it works—and how it's transforming the way we treat cancer.

The pathway and impact of cancer-related data



Greater cancer insight with cutting-edge technology from Quest Diagnostics

IBM Watson Genomics from Quest Diagnostics combines Quest's state-of-the-art tumor analysis with the cognitive computing of IBM Watson and the deep cancer treatment expertise of Memorial Sloan Kettering Cancer Center. The test identifies:

Single nucleotide variants | Insertions and deletions | Copy number variations | Select rearrangements in 50 genes

References

1. Stephens ZD, Lee SY, Faghri F, et al. Big data: astronomical or genomics? *PLOS Biology*. 2015;13(7):e1002195.
2. Harley L. A disease of the genome. *Front Line Genomics Magazine*. Oct 2016.
3. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas. *Clinical Cancer Research*. 2015. DOI: 10.1158/1078-0432.CCR-14-2683.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2018 Quest Diagnostics Incorporated. All rights reserved. MI7857 9/2018